These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 26849078)

  • 21. Antileukemia activity of a natural killer cell line against human leukemias.
    Yan Y; Steinherz P; Klingemann HG; Dennig D; Childs BH; McGuirk J; O'Reilly RJ
    Clin Cancer Res; 1998 Nov; 4(11):2859-68. PubMed ID: 9829753
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cord blood-derived cytokine-induced killer cells combined with blinatumomab as a therapeutic strategy for CD19
    Golay J; Martinelli S; Alzani R; Cribioli S; Albanese C; Gotti E; Pasini B; Mazzanti B; Saccardi R; Rambaldi A; Introna M
    Cytotherapy; 2018 Aug; 20(8):1077-1088. PubMed ID: 30093325
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The cytotoxic action of the CD56+ fraction of cytokine-induced killer cells against a K562 cell line is mainly restricted to the natural killer cell subset.
    Chieregato K; Zanon C; Castegnaro S; Bernardi M; Amati E; Sella S; Rodeghiero F; Astori G
    Blood Transfus; 2017 Jan; 15(1):93-100. PubMed ID: 27136441
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ex vivo expansion of natural killer cells for clinical applications.
    Klingemann HG; Martinson J
    Cytotherapy; 2004; 6(1):15-22. PubMed ID: 14985163
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Expansion of cytotoxic CD3+ CD56+ cells from peripheral blood progenitor cells of patients undergoing autologous hematopoietic cell transplantation.
    Alvarnas JC; Linn YC; Hope EG; Negrin RS
    Biol Blood Marrow Transplant; 2001; 7(4):216-22. PubMed ID: 11349808
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CIK cells from recurrent or refractory AML patients can be efficiently expanded in vitro and used for reduction of leukemic blasts in vivo.
    Wang Y; Bo J; Dai HR; Lu XC; Lv HY; Yang B; Wang T; Han WD
    Exp Hematol; 2013 Mar; 41(3):241-52.e3. PubMed ID: 23123634
    [TBL] [Abstract][Full Text] [Related]  

  • 27. High log-scale expansion of functional human natural killer cells from umbilical cord blood CD34-positive cells for adoptive cancer immunotherapy.
    Spanholtz J; Tordoir M; Eissens D; Preijers F; van der Meer A; Joosten I; Schaap N; de Witte TM; Dolstra H
    PLoS One; 2010 Feb; 5(2):e9221. PubMed ID: 20169160
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A good manufacturing practice method to ex vivo expand natural killer cells for clinical use.
    Torelli GF; Rozera C; Santodonato L; Peragine N; D'agostino G; Montefiore E; Napolitano MR; Monque DM; Carlei D; Mariglia P; Pauselli S; Gozzer M; Bafti MS; Girelli G; Guarini A; Belardelli F; Foà R
    Blood Transfus; 2015 Jul; 13(3):464-71. PubMed ID: 25761309
    [TBL] [Abstract][Full Text] [Related]  

  • 29. NK cell maturation to CD56(dim) subset associated with high levels of NCRs overrides the inhibitory effect of NKG2A and recovers impaired NK cell cytolytic potential after allogeneic hematopoietic stem cell transplantation.
    Ghasemzadeh M; Hosseini E; Schwarer AP; Pourfathollah AA
    Leuk Res; 2016 Apr; 43():58-65. PubMed ID: 26856773
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Anti-CD3 + interleukin-2 stimulation of marrow and blood: comparison of proliferation and cytotoxicity.
    Anderson PM; Ochoa AC; Ramsay NK; Hasz D; Weisdorf D
    Blood; 1992 Oct; 80(7):1846-53. PubMed ID: 1391948
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of interleukin-12 on antitumor activity of human umbilical cord blood and bone marrow cytotoxic cells.
    Condiotti R; Nagler A
    Exp Hematol; 1998 Jul; 26(7):571-9. PubMed ID: 9657131
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Low dose subcutaneous interleukin-2 after autologous transplantation generates sustained in vivo natural killer cell activity.
    Miller JS; Tessmer-Tuck J; Pierson BA; Weisdorf D; McGlave P; Blazar BR; Katsanis E; Verfaillie C; Lebkowski J; Radford J; Burns LJ
    Biol Blood Marrow Transplant; 1997 Apr; 3(1):34-44. PubMed ID: 9209739
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Natural killer and lymphokine-activated killer cell activities from human marrow precursors. II. The effects of IL-3 and IL-4.
    Keever CA; Pekle K; Gazzola MV; Collins NH; Bourhis JH; Gillio A
    J Immunol; 1989 Nov; 143(10):3241-9. PubMed ID: 2809200
    [TBL] [Abstract][Full Text] [Related]  

  • 34. NK cell activity in tuberculosis is associated with impaired CD11a and ICAM-1 expression: a regulatory role of monocytes in NK activation.
    Schierloh P; Alemán M; Yokobori N; Alves L; Roldán N; Abbate E; del C Sasiain M; de la Barrera S
    Immunology; 2005 Dec; 116(4):541-52. PubMed ID: 16313368
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Good manufacturing practices production of natural killer cells for immunotherapy: a six-year single-institution experience.
    McKenna DH; Sumstad D; Bostrom N; Kadidlo DM; Fautsch S; McNearney S; Dewaard R; McGlave PB; Weisdorf DJ; Wagner JE; McCullough J; Miller JS
    Transfusion; 2007 Mar; 47(3):520-8. PubMed ID: 17319835
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Abrogation of graft-vs.-leukemia activity after depletion of CD3+ T cells in a murine model of MHC-matched peripheral blood progenitor cell transplantation (PBPCT).
    Uharek L; Glass B; Zeis M; Dreger P; Steinmann J; Löffler H; Schmitz N
    Exp Hematol; 1998 Feb; 26(2):93-9. PubMed ID: 9472798
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CD3+/CD19+-depleted grafts in HLA-matched allogeneic peripheral blood stem cell transplantation lead to early NK cell cytolytic responses and reduced inhibitory activity of NKG2A.
    Eissens DN; Schaap NP; Preijers FW; Dolstra H; van Cranenbroek B; Schattenberg AV; Joosten I; van der Meer A
    Leukemia; 2010 Mar; 24(3):583-91. PubMed ID: 20033055
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Characterization of cord blood natural killer and lymphokine activated killer lymphocytes following ex vivo cellular engineering.
    Ayello J; van de Ven C; Fortino W; Wade-Harris C; Satwani P; Baxi L; Simpson LL; Sanger W; Pickering D; Kurtzberg J; Cairo MS
    Biol Blood Marrow Transplant; 2006 Jun; 12(6):608-22. PubMed ID: 16737934
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Culture of normal and leukemic bone marrow in interleukin-2: analysis of cell activation, cell proliferation, and cytokine production.
    Klingemann HG; Neerunjun J; Schwulera U; Ziltener HJ
    Leukemia; 1993 Sep; 7(9):1389-93. PubMed ID: 8371589
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunological aspects of allogeneic and autologous mesenchymal stem cell therapies.
    Hoogduijn MJ; Roemeling-van Rhijn M; Korevaar SS; Engela AU; Weimar W; Baan CC
    Hum Gene Ther; 2011 Dec; 22(12):1587-91. PubMed ID: 21732766
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.